ReviewClinical and translational medicine2026
Lactate metabolism and lactylation in female reproductive diseases: From metabolic rewiring to biomarkers and translational therapeutics.
Review in Clinical and translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundLactate is increasingly recognized not only as a metabolic end product of glycolysis but also as a signaling metabolite that links metabolic reprogramming to epigenetic and transcriptional regulation through protein lactylation. Emerging evidence suggests that the lactate-lactylation axis contributes to the pathogenesis of female reproductive diseases, including endometriosis, endometrial cancer, polycystic ovary syndrome, and ovarian cancer. MAIN BODY: This review summarizes current evidence on lactate production, lactate transport, and histone/non-histone lactylation in female reproductive diseases. Available studies indicate that aberrant lactate accumulation and lactylation may influence chromatin accessibility, transcription factor activity, immune remodeling, ferroptosis resistance, steroidogenic dysfunction, and DNA damage repair. These processes may contribute to disease progression and may provide candidate biomarkers or therapeutic targets, including lactylation-related enzymes, lactate transporters, glycolytic regulators, and lactate-depleting strategies. However, the current evidence base remains dominated by cell and animal studies, and major barriers persist, including incomplete identification of bona fide reader proteins, insufficient standardization of site-specific lactylation detection, limited validation in human cohorts, and uncertainty regarding disease specificity.
conclusionThe lactate-lactylation axis provides a useful framework for understanding metabolic-epigenetic coupling in female reproductive diseases and may inform future biomarker development, patient stratification, and mechanism-based therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.